Zimbabwe has rejected a substantial US health deal worth $367m (272 million pounds) spanning five years over Washington's insistence on sensitive biological samples.
This rejection came to light after a official document dated December was leaked, revealing that President Emmerson Mnangagwa deemed the deal was "lopsided".
An official representative later explained that the United States was seeking biological samples for scientific study and commercial gain while was unwilling to share the benefits from future vaccines.
"We will now turn to the difficult and regrettable process of scaling back our health aid in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had provided over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has appealed for more talks to reach a deal acceptable to both sides so the country's critical HIV programme can be sustained.
Wider Implications
This development follows a comparable situation in Kenya, where a court halted a related deal with the US after concerns were filed about the safety of Kenyans' medical information.
After returning to the presidency recently, US President Donald Trump has reduced overseas assistance and closed the key foreign aid agency.
USAID had managed aid for the US government, but Trump claimed its spending was "wasteful" and his administration was seeking government-to-government deals to enhance openness and responsibility.
Based on statements, Sixteen nations in Africa have to date signed similar health pacts, representing over $18.3bn in new funding.
Details of the Declined Deal
The money for Zimbabwe would have supported "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this collaboration would have delivered extraordinary benefits for Zimbabwean communities, especially the 1.2 million men, women and children presently receiving HIV treatment via US-supported programmes," the Ambassador commented.
However, government spokesperson Nick Mangwana argued the arrangement was "unfair".
"The proposal required Zimbabwe to surrender its biological resources and data indefinitely, with no equivalent promise of access to any medical innovations – like new medicines or tests – that might be developed from that provided information," his statement read.
"Effectively, our country would supply the basic resources for medical research with no certainty that the resulting innovations would be available to our population if a future disease outbreak arise."
National Interest and Global Health
Mangwana further said that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were upending systems already established via the global organization.
The spokesperson cited its Pathogen Access and Benefit Sharing framework created to manage potential pandemics.
"This system is intended to ensure that when a country contributes its information, the resulting advantages – including vaccines and treatments – are distributed fairly, not monopolised solely by those with the capability to develop them."
These objections regarding the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We welcome ongoing dialogue with our American counterparts on how subsequent co-operation might be structured in a manner that respects the sovereignty and interests of both nations."
Health Experts Reaction
A leading public health body stated it acknowledged the government's concerns, but recommended that talks should continue since much of the country's Aids initiatives were funded by foreign aid.
"Where technical issues arise, including those involving information security or implementation frameworks, these can frequently be addressed via technical clarification and negotiated safeguards," it added.
The situation highlights the complex debate between receiving crucial international aid and safeguarding a country's data in an ever more data-driven world.